Cancer Genetics and Epigenetics 2024, Vol.12, No.6, 317-328 http://medscipublisher.com/index.php/cge 328 Tsubaki M., Takeda T., Noguchi M., Jinushi M., Seki S., Morii Y., Shimomura K., Imano M., Satou T., and Nishida S., 2019, Overactivation of Akt contributes to mek inhibitor primary and acquired resistance in colorectal cancer cells, Cancers, 11(12): 1866. https://doi.org/10.3390/cancers11121866 PMID: 31769426 PMCID: PMC6966459 Verbanac D., Čeri A., Hlapčić I., Shakibaei M., Brockmueller A., Krušlin B., Ljubičić N., Baršić N., Detel D., Batičić L., Rumora L., Somborac-Bačura A., Štefanović M., Ćelap I., Demirović A., Petlevski R., Petrik J., Rajković M., Hulina-Tomašković A., Rako I., Saso L., and Barišić K., 2021, Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy, International Journal of Molecular Sciences, 22(9): 4327. https://doi.org/10.3390/ijms22094327 PMID: 33919272 PMCID: PMC8122648 Wang F., Zhao Q., Jiang T.J., Wang Y.N., Liu F.R., Hu J.J., Ding P.R., Pan Z.Z., Shao J.Y., and Xu RH.., 2019, Abstract 4161: Germline mutational profileof Chinese patients with colorectal cancer and diagnosed lower than 70 years, Epidemiology, 79(13_Supplement): 4161. https://doi.org/10.1158/1538-7445.AM2019-4161 Wu C.W.K., Reid M., Leedham S., and Lui R.N., 2022, The emerging era of personalized medicine in advanced colorectal cancer, Journal of Gastroenterology and Hepatology, 37(8): 1411-1425. https://doi.org/10.1111/jgh.15937 PMID: 35815339 PMCID: PMC7617119 Yamada T., Matsuda A., Takahashi G., Iwai T., Takeda K., Ueda K., Kuriyama S., Koizumi M., Shinji S., Yokoyama Y., Ohta R., and Yoshida H., 2020, Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy, International Journal of Clinical Oncology, 25(8): 1523-1532. https://doi.org/10.1007/s10147-020-01691-0 PMID: 32394048 Yan F., Gao W., Zhu L.F., Xie W.Z., Gao C., Zhao J., Huang M.L., Cai S.L., and Zhong Y., 2019, Circulating tumor DNA-based mutational landscape of advanced colorectal cancer, Journal of Clinical Oncology, 37: e15034-e15034 https://doi.org/10.1200/JCO.2019.37.15_SUPPL.E15034 Yang M.L., Schell M., Loboda A., Nebozhyn M., Pledger W.J., and Yeatman T., 2020, Abstract 5789: A novel role of APC-partnering mutations in the sidedness of colorectal cancer survival, Cancer Research, 80(16_Supplement): 5789-5789. https://doi.org/10.1158/1538-7445.am2020-5789 Ye J., Lin M., Zhang C.M., Zhu X.W., Li S.M., Liu H., Yin J.F., Yu, H., and Zhu K.C., 2020, Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications, Biomedical Reports, 13(1): 43-48. https://doi.org/10.3892/br.2020.1303 PMID: 32440349 PMCID: PMC7238404 Zhuang Y., Wang H.L., Jiang D., Li Y., Feng L.X., Tian C.J., Pu M.Y., Wang X.W., Zhang J.Y., Hu Y.J., and Liu P.F., 2021, Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis, BMC Cancer, 21(1): 380. https://doi.org/10.1186/s12885-021-08108-9 PMID: 33836681 PMCID: PMC8034139
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==